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Abstract 
Background: Lung cancer is the leading cause of cancer‑related morbidity and mortality worldwide. Patients with 
chronic respiratory diseases, such as chronic obstructive pulmonary disease (COPD), are exposed to a higher risk of 
developing lung cancer. Chronic inflammation may play an important role in the lung carcinogenesis among those 
patients. The present study aimed at identifying candidate biomarker predicting lung cancer risk among patients with 
chronic respiratory diseases.
Methods: We applied clinical bioinformatics tools to analyze different gene profile datasets with a special focus on 
screening the potential biomarker during chronic inflammation‑lung cancer transition. Then we adopted an in vitro 
model based on LPS‑challenged A549 cells to validate the biomarker through RNA‑sequencing, quantitative real time 
polymerase chain reaction, and western blot analysis.
Results: Bioinformatics analyses of the 16 enrolled GSE datasets from Gene Expression Omnibus online database 
showed myocyte enhancer factor 2D (MEF2D) level significantly increased in COPD patients coexisting non‑small‑cell 
lung carcinoma (NSCLC). Inflammation challenge increased MEF2D expression in NSCLC cell line A549, associated 
with the severity of inflammation. Extracellular signal‑regulated protein kinase inhibition could reverse the up‑regu‑
lation of MEF2D in inflammation‑activated A549. MEF2D played a critical role in NSCLC cell bio‑behaviors, including 
proliferation, differentiation, and movement.
Conclusions: Inflammatory conditions led to increased MEF2D expression, which might further contribute to the 
development of lung cancer through influencing cancer microenvironment and cell bio‑behaviors. MEF2D might be 
a potential biomarker during chronic inflammation‑lung cancer transition, predicting the risk of lung cancer among 
patients with chronic respiratory diseases.
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Background
Lung cancer is the most prevalent malignant tumor and 
the leading cause of cancer-related morbidity and mor-
tality worldwide [1], mainly cataloged into non-small-cell 
lung carcinoma (NSCLC), large-cell carcinoma (LCC), 
and small-cell lung carcinoma (SCLC). Patients with 
chronic respiratory diseases are predisposed to higher 
incidence of lung cancer [2–7]. Chronic obstructive pul-
monary disease (COPD), a chronic inflammatory lung 
disease, is closely related to susceptibility to lung cancer 
and stands as the most important risk factor of lung can-
cer among smokers [8]. Patients with moderate-to-severe 
COPD have a fivefold higher risk of developing lung can-
cer than smokers without the disease [9]. Chronic inflam-
mation associated with COPD seems to play a critical 
role in cancer evolution. However, there is limited knowl-
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lung cancer is triggered. The emergency of genomics and 
clinical bioinformatics allows defining gene alterations 
during the process of carcinogenesis to further under-
stand the relationship between chronic inflammation and 
the onset of lung cancer.
The myocyte enhancer factor 2 (MEF2) family of 
human transcription factors, consisting of four subtypes, 
MEF2-A, -B, -C and -D, have a diversity of functions in 
different tissues and have been implicated in numerous 
diseases. MEF2s play an important role in the activation 
of the genetic processes that control cell differentiation, 
proliferation, and apoptosis in a wide range of cell types 
[10]. It has been reported that MEF2 is correlated with 
lower physical activity in COPD patients [11]. Altered 
MEF2 activity has been revealed as driver of cancer 
development, including both hematological cancers and 
solid tumor. Recent study found that MEF2 genes might 
act as oncogenes in NSCLC [12].
The present study is aimed to figure out candidate 
“communicator” between chronic inflammation and lung 
cancer and determine the potential regulatory mecha-
nism. We highlight studies exploring the link between 
inflammation and cancer and discuss emerging bio-
marker for predicting risk of lung cancer among patients 
with chronic respiratory diseases.
Methods
Bioinformatics tools
We used “lung cancer” as the search keyword and 
“human” as organism to search for GSE datasets in Gene 
Expression Omnibus (GEO) online database. GSE data-
sets containing comparative gene expression profiling 
between lung cancer and non-cancer tissues, pathological 
definitions, and information of data normalizing methods 
were enrolled in the present study. Gene expression pro-
filing data of each dataset were restored to original data, 
re-normalized with reference genes, and transformed to 
the ratio of expression data, and then integrated into one 
dataset. Genes with twofolds and more than twofolds up 
or down change in lung cancer subtypes were thought to 
be significantly differential genes, compared with non-
cancer tissues. All the differential genes were used in fur-
ther bioinformatics analysis.
Cell culture
Human NSCLC cell line A549 cells, human bronchial epi-
thelial cell line HBE cells, and human normal bronchial epi-
thelial cell line BEAS-2B cells were obtained from Shanghai 
Institute for Biological Science. Cells were cultured in 
DMEM (high glucose, Hyclone, Logan, UT, USA), supple-
mented with 10% FBS (Hyclone, Logan, UT, USA), 100 U/
ml penicillin, and 100 μg/ml streptomycin at 37 °C in a 5% 
CO2, 95% air environment in humidified incubators.
Ion Torrent‑based RNA‑sequencing
RNA extraction was performed using the TRIZOL™LS 
reagent (Invitrogen, Carlsbad, CA, USA). rRNA deple-
tion was performed using the RiboMinus™ Eukaryote 
System v2 (Ambion®) following standard protocols. First, 
total RNA was hybridized with biotinylated RiboMinus™ 
Eukaryote Probe Mix v2. Next, the rRNA-probe com-
plexes were removed from the total RNA by captured 
with streptavidin-conjugated RiboMinus™ Magnetic 
Beads. The resulting rRNA-depleted RNA was concen-
trated and purified with Nucleic Acid Binding Beads. The 
cDNA libraries were barcoded using the ion total RNA-
Seq Kit v2 (Ambion®) following standard protocols. RNA 
sequencing was performed on the Ion Proton™ System 
(Life Technologies, Carlsbad, CA, USA). Data analysis was 
performed using Torrent Suite™ Software 4.0 (Ion Tor-
rent). Genes with twofolds and more than twofolds up or 
down change in LPS-stimulated A549 cells were thought 
to be significant, compared with the control group.
Quantitative real time polymerase chain reaction 
(qRT‑PCR) analysis
RNA extraction was performed using the TRIZOL™LS 
reagent (Invitrogen, Carlsbad, CA, USA). cDNA was pre-
pared using PrimeScript® RT reagent Kit (Takara, Shiga, 
Japan) following standard protocols. qRT-PCR was per-
formed using SYBR® Premix Ex Taq™ (Takara, Shiga, 
Japan) on the ABI 7000 PCR instrument (Eppendorf, 
Hamburg, Germany) with the following two-stage pro-
gram parameters: 1 min at 95 °C and then 40 cycles of 5 s 
at 95 °C and 30 s at 60 °C. All samples were run in tripli-
cate, and each group had six wells. Results were shown as 
relative target mRNA levels. The sequences of the prim-









 GAPDH Forward, 5′-CCACCCATGGCAAATTCCATG 
GCA-3′,
 GAPDH Reverse, 5′-TCTACACGGCAGGTCAGGTC 
CACC-3′.
Western bolt analysis
Intracellular protein was extracted by radio immuno-
precipitation assay lysis buffer. Protein samples (50  μg) 
were mixed with an equal volume of 5× sodium dode-
cyl sulfate buffer, boiled for 5  min, and then separated 
through 10% sodium dodecyl sulfate-polyacrylamide gel 
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electrophoresis gels. Proteins were transferred to polyvi-
nylidene fluoride membranes by electrophoretic transfer 
after electrophoresis. Membranes were blocked in 5% dry 
milk for 2 h, rinsed, and incubated with primary antibod-
ies (diluted at their instructions) in TBS thrice at 4  °C 
overnight. Primary antibody was then removed by wash-
ing in TBS and labeled by incubating with 0.1  mg/ml 
peroxidase-labeled secondary antibodies (against mouse 
and rabbit) for 2 h. Following three washes in TBS, bands 
were visualized by ECL (Tanon, Shanghai, China) and 
exposed to X-ray film. The band densities were quantified 
with Image J. The results were presented as ratio of band 
density to total actin.
Small interfering RNA (siRNA) transfection
Three different sequences targeting MEF2D (Additional 
file 1: Table S1) were designed and provided by GeneP-
harma (Shanghai, China). siRNA transfection was per-
formed according to the manufacturer’s protocol. Briefly, 
1 μl Lipofectamine 2000 and 50 pmol each siRNA were 
mixed. Cells were then transfected with Lipofectamine/
siRNA complexes and incubated at 37 °C for 24 h. Trans-
fection efficiency was evaluated by qRT-PCR and West-
ern Blot analysis. Clones with optimized transfection 
were selected for stable transfection of MEF2D and used 
in the experiments.
Alive measurement of cell bio‑behaviors
The cell bio-behaviors including total cell number, cell 
differentiation, and cell movement were dynamically 
measured through a Cell-IQ platform (Chip-Man Tech-
nologies, Tampere, Finland), equipped with a phase-con-
trast microscope (Nikon CFI Achromat phase contrast 
objective with ×10 magnification) and a camera (Nikon, 
Fukasawa, Japan). The equipment was controlled by Ima-
gen software (Chip-Man Technologies). Images were 
captured every 5 min for 72 h. Analysis was carried out 
with a freely distributed Image software (Cell-IQ Ima-
gen v2.9.5c; McMaster Biophotonics Facility, Hamilton, 
ON, Canada), using the Manual Tracking plug-in created 
by Fabrice Cordelieres (Institut Curie, Orsay, France). 
Cell-IQ system can monitor and record time-lapse data 
through machine vision technology, as well as analyze 
and quantify cell functions and morphological param-
eters. Here, we use this system to calculate cell numbers 
of each stage (dividing/stable stage) during proliferation, 
discriminate cell stage, and quantify the movement of 
each individual cell. Each group contained 6–12 replicate 
image sites.
Cell migration assay
In the Transwell assay (Corning Inc., Corning, NY, 
USA), cells were seeded in the upper chamber at the 
concentration of 5  ×  105/ml in serum-free medium, 
while medium containing 10% FBS was added to the 
lower chamber. Cells migrated through the permeable 
membrane at 48 h were fixed and stained with Giemsa, 
and then counted under microscope.
Cell proliferation assay
In the cell proliferation assay, cells were seeded in 96-well 
plates at the concentration of 1 × 104/well and incubated 
with AR (40 ng/ml) for 24, 48 or 72 h at 37  °C with 5% 
CO2, after which 10  μl of the Cell Counting Kit-8 solu-
tion (Dojindo, Japan) was added to the medium. After 
2-h incubation, the amount of orange formazan dye gen-
erated was determined by measuring the absorbance at 
450  nm under microplate reader (Thermo Scientific, 
Carlsbad, CA, USA).
Statistical analysis
All values were expressed as mean  ±  SEM. Statistical 
analysis was performed using SPSS software (SPSS 20.0; 
SPSS Inc; Chicago, IL, USA). Values between lung cancer 
subtypes were analyzed with Students’s t test and Mann–
Whitney U test. Data were evaluated using ANOVA with 
LSD test for multiple comparisons and Students’s t test 
between two groups. p < 0.05 was considered as statisti-
cal significant.
Results
Elevated MEF2D level in COPD patients with NSCLC
16 GSE datasets containing comparative gene expression 
profiles of lung cancer and non-cancer tissues, patho-
logical definitions, and information of data normalizing 
methods were enrolled in the present study through clin-
ical bioinformatics tools. There were totally 677 NSCLC, 
9 LCC, 56 SCLC cases, and 590 non-cancer cases. In 
patients with NSCLC, the expressions of MEF2A and 
MEF2D were significantly higher, compared with non-
cancer tissues (Fig. 1a, p < 0.01 and 0.001, respectively). 
In patients with LCC or SCLC, the expressions of MEF2A 
were significantly lower, compared with non-cancer tis-
sues (Fig.  1b, c, p  <  0.01, and 0.001, respectively). The 
MEF2D levels were also decreased in patients with LCC 
or SCLC as compared with non-cancer tissues (Fig.  1b, 
c). Further data mining demonstrated significantly higher 
MEF2D level in COPD patients with NSCLC than that in 
smokers, patients with COPD and no NSCLC, or patients 
with NSCLC and no COPD, compared with healthy non-
smokers (Fig. 1d, p < 0.001).
Increased MEF2D expression inflammation‑activated 
NSCLC cell line
We carried out Ion Torrent-based RNA-sequencing in 
a model of LPS-challenged NSCLC cell line A549. A549 
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cells were stimulated with vehicles or LPS at 0.1, 1  μg/
ml for 4  h or 8  h, respectively. Figure  2a demonstrated 
the top ten genes up-expressed over twofold: HDAC4, 
HIST1H4J, EP300, HDAC5, CABIN1, GDF2, MEF2D, 
C1orf21, HIST1H2AK, and NKX2-8, as well as the 
top ten genes down-expressed over twofold: NR4A1, 
NFATC2, YWHAQ, CAMK4, FOS, KIAA1009, DKK3, 
NLRP13, MDK, and PRMT6, in LPS-stimulated A549 
cells. Figure 2b showed the gene network associated with 
MEF2D.
MEF2D specifically up‑regulated in inflammation‑activated 
NSCLC cell line
We investigated MEF2s gene expression in different lung 
cell lines through qRT-PCR analysis. We found that LPS 
challenge significantly up-regulated the mRNA levels of 
MEF2D in NSCLC cell line A549 cells, as compared with 
those stimulated with vehicle, in accordance with the 
RNA-seq results (Fig.  3a). The mRNA levels of MEF2D 
were also up-regulated in HBE cells after LPS stimulation, 
but the fold changes were lower than those in LPS-acti-
vated A549 cells (Fig. 3b). As shown in Fig. 3c, levels of 
MEF2D were not significantly altered in BEAS-2B cells.
MEF2D expressions increased associated with the severity 
of inflammation
The mRNA expressions of MEF2D in LPS-stimulated 
A549 cells increased in a concentration-dependent 
pattern and reached to the highest level when LPS 
concentration was 1  μg/ml (Fig.  4a, p  <  0.001). LPS-
stimulated expression of MEF2D mRNA increased in a 
time-dependent pattern as well, and reached to the high-
est level at 24 h after LPS stimulation (Fig. 4b, p < 0.001). 
The protein expressions of MEF2D also increased in 
a concentration- or time-dependent pattern after LPS 
stimulation, and reached to the highest level when LPS 
concentration was 1 μg/ml (Fig. 4c, p < 0.01) or at 72 h 
after LPS stimulation (Fig. 4d, p < 0.01), respectively, in 
accordance with the mRNA expressions.
MEF2D‑deficiency impaired NSCLC cell bio‑behaviors
We used the real-time cell monitoring system to investigate 
the effect of MEF2D on cell bio-behaviors. We found that 
MEF2D-deficiency significantly reduced the capacity of cell 
proliferation (Fig. 5a), differentiation (Fig. 5b) or movement 
(Fig. 5c) in NSCLC cell line A549 cells, compared with the 
control cells. The role of MEF2D in A549 cells migration 
Fig. 1 Expressions of MEF2 family genes in patients with lung cancer. The expression of MEF2s in patients with non‑small‑cell lung carcinoma 
(NSCLC) (a), large‑cell carcinoma (LCC) (b), small‑cell lung carcinoma (SCLC) (c). **p < 0.01, and ***p < 0.001, as compared with genes in non‑cancer 
tissues. The expression of MEF2D in smokers, COPD patients, NSCLC patients, and COPD patients coexisting NSCLC (d). *p < 0.05, and ***p < 0.001, 
as compared with genes in healthy non‑smokers
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was further investigated by Transwell assay. As shown in 
Fig. 5d1, d2, MEF2D-knockdown A549 cells by siRNA had 
significantly impaired capacity of migration toward 10% 
FBS, compared with the control cells (p < 0.01). The role of 
MEF2D in A549 cells proliferation was further investigated 
by CCK-8 assay. As shown in Fig. 5e, capacity of cell pro-
liferation was significantly reduced in MEF2D-knockdown 
A549 cells, compared with the control cells.
Extracellular signal‑regulated protein kinase 
(ERK) inhibition reversed up‑regulation of MEF2D 
in inflammation‑activated NSCLC cell line
A549 cells respectively pretreated with ERK inhibitor 
PD98059 or PI3 K inhibitor LY290042 at doses of 10, 20 
and 30 μM for 2 h were then challenged with vehicle or 
LPS at the concentration of 1 μg/ml for 48 h. Treatment 
with PD98509 significantly reversed LPS-induced up-
regulation of MEF2D (Fig. 6a, p < 0.05), while treatment 
with LY290042 did not alter the LPS-induced MEF2D 
expression significantly (Fig. 6b).
Discussion
MEF2D, a transcription factor of the MEF2 family, is not 
only critical for myogenesis, but also plays an important 
role in regulating diverse developmental programs [13]. It 
has been implicated that MEF2D is involved in different 
types of malignancies, including acute lymphoblastic leu-
kemia, hepatocellular carcinoma and osteosarcoma [14–
18]. Recently, MEF2D has been reported to promote the 
growth of lung cancer [19]. In this study, we found that 
MEF2D was overexpressed in clinical NSCLC tissues. 
Further data mining showed significantly higher MEF2D 
level in COPD patients with NSCLC than that in smok-
ers, patients with COPD and no NSCLC, or patients with 
NSCLC and no COPD. Growing evidence has shown 
that patients with chronic respiratory conditions such as 
COPD exhibit a significantly higher risk of lung cancer 
[8]. It is reported that 50–90% lung cancer patients have 
coexisting COPD [20]. Chronic inflammation associated 
with COPD seems to be a critical player in lung cancer 
development and prognosis [21, 22], related to 15–20% of 
cancer deaths [23], while little is known about the under-
lying mechanism. The results prompted us to further 
speculate whether MEF2D might act as a communicator 
between inflammation and lung cancer.
The present study adopted an in  vitro model based 
on LPS-stimulated A549 to explore the underlying link 
between inflammation and lung cancer. Our data showed 
that MEF2D expression was significantly elevated in 
inflammation-activated NSCLC cell line A549 through 
Fig. 2 Alterations of gene clusters in inflammation‑activated NSCLC cell line. a The top ten genes expression more than twofold up‑ or down‑
expressed in LPS‑stimulated A549 cells; b genes associated with MEF2D network
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Ion Torrent-based RNA-sequencing analysis, as were 
genes associated with MEF2D network. LPS challenge 
specifically up-regulated the MEF2D mRNA expression 
in A549 significantly rather than in bronchial epithelial 
cell lines HBE or BEAS-2B cells. Our data also demon-
strated that LPS challenge up-regulated the mRNA or 
protein levels of MEF2D in A549 in a LPS-concentration 
dependent and time dependent manner. It seems that the 
influencing roles of inflammation in the expression of 
MEF2D are related with the severities.
Diverse calcium-dependent signaling pathways have 
been revealed as regulators of MEF2 activity, including 
calcium/calmodulin-dependent protein kinase (CaMK) 
signaling, calcineurin signaling, and mitogen-activated 
protein kinase (MAPK) signaling [10]. MAPKs are mainly 
divided into three signaling cascades: ERK, p38 kinase 
and c-jun N-terminal kinase (JNK) pathways. In accord-
ance with the previous study [24], we found that the ERK 
signaling pathway may play the critical and dependent 
role in the mechanism of MEF2D production of A549, 
evidenced by the finding that the over-production of 
MEF2D by LPS-challenge was prevented by ERK inhibi-
tor. Further study is needed to demonstrate MEF2D tar-
geted genes after inflammation challenge.
Inflammation plays multifaceted roles in all stages 
of tumorigenesis, including malignant transformation, 
tumor initiation to invasion, and metastasis of estab-
lished tumor [25]. Cancer-related inflammatory micro-
environment, mainly composed of inflammatory cells 
and mediators, has been accepted as a significant factor 
through which inflammation contributes to the multiple 
capabilities of cancer [26]. Our previous study reported 
Fig. 3 mRNA expression of MEF2s in different LPS‑activated lung cell lines. a qRT‑PCR analysis of MEF2s expression in total mRNA harvested from 
A549 cells challenged with PBS (LPS 0 μg/ml) or LPS at 0.01, 0.1, 1 μg/ml for 4 h; b qRT‑PCR analysis of MEF2s expression in total mRNA harvested 
from HBE cells challenged with PBS (LPS 0 μg/ml) or LPS at 0.01, 0.1, 1 μg/ml for 4 h; c qRT‑PCR analysis of MEF2s expression in total mRNA har‑
vested from BEAS‑2B cells challenged with PBS (LPS 0 μg/ml) or LPS at 0.01, 0.1, 1 μg/ml for 4 h. Data were presented as mean ± S.E.M and each 
group had at least six measurements (*p < 0.05, **p < 0.01, ***p < 0.001, as compared with control group)
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that inflammation-activated lung cells could act as the 
initiators and/or secondary sources of the development 
of cancer microenvironment [27]. Consistent with our 
previous study, we provide further evidence that inflam-
matory conditions might contribute to remodeling of the 
cancer microenvironment through up-regulating MEF2D 
expression.
During a host response to bacterial pathogens, activa-
tion of MEF2 by p38 kinase pathway has been related to 
expression of pro-inflammatory cytokines [28]. In pri-
mary human T lymphocytes, MEF2D is required for the 
synthesis of IL-2 mRNA and secretion of IL-2 in response 
to T cell receptor stimulation [29]. MEF2 participates in 
the regulation of B lymphocyte proliferation and survival 
after B cell receptor stimulation [30]. MEF2D is identified 
as an important regulator of IL-10 gene expression [31]. 
Given the critical roles of MEF2 in regulation of inflam-
matory responses, up-regulation of MEF2D might lead 
to remodeling of cancer microenvironment through lym-
phocytes recruitment or mediators production during 
inflammatory condition. Further in vitro study is needed 
to clarify the underlying mechanism.
MEF2D has been reported to serve as oncogene in B 
cell acute lymphoblastic leukemia [15] and hepatocellu-
lar carcinoma [16, 32–34] through promotion of colony 
formation and proliferation, inhibition of apoptosis, epi-
thelial-mesenchymal transition and invasiveness. MEF2D 
also acts as tumor suppressor in liposarcoma, leiomyo-
sarcoma [35] and rhabdomyosarcoma [36, 37] through 
promotion of cell proliferation and anchorage independ-
ent growth and inhibition of differentiation. Consistent 
with the previous studies, we found that MEF2D played 
a critical role in bio-behaviors of NSCLC cells. While tar-
geted knockdown of MEF2D gene via siRNA significantly 
impaired the capacity of cancer cell differentiation, pro-
liferation or movement. Up-regulation of MEF2D during 
Fig. 4 Expressions of MEF2D in LPS‑activated NSCLC cell line. a qRT‑PCR analysis of MEF2D mRNA expression in total mRNA harvested from A549 
cells challenged with PBS (LPS 0 μg/ml) or LPS at 0.01, 0.1, 1 μg/ml for 4 h; b qRT‑PCR analysis of MEF2D mRNA expression in total mRNA harvested 
from A549 cells challenged with LPS at 1 μg/ml from 0 to 24 h; c Western blotting analysis of MEF2D protein expression in A549 cells challenged 
with PBS (LPS 0 μg/ml) or LPS at 0.01, 0.1, 1 μg/ml for 48 h; d Western blotting analysis of MEF2D protein expression in A549 cells challenged with 
LPS at 1 μg/ml from 0 to 72 h. Data were presented as mean ± S.E.M and each group had at least six measurements (**p < 0.01, ***p < 0.001, as 
compared with control group)
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inflammatory condition might favor lung cancer cell dif-
ferentiation, proliferation, or movement.
Briefly, inflammatory conditions led to increased 
MEF2D expression, which might further contribute to 
the development of malignancy through influencing 
cancer microenvironment and cell bio-behaviors. As far 
as we know, this is the first study focused on MEF2D as 
a “communicator” between chronic inflammation and 
Fig. 5 Interference of MEF2D expression impaired cell bio‑behaviors in cultures of NSCLC cell line. Dynamic alterations of the cells proliferation 
(a), differentiation (b), and movement (c) by Cell‑IQ Alive Image Monitoring System. d1 Effects of MEF2D on A549 migration by Transwell assay. 
Figures showed Giemsa stained A549 which migrated through the permeable membrane at 48 h. Migration of MEF2D‑knockdown A549 by SiRNA 
toward 10% FBS was significantly reduced compared to the control group. d2 Average cell numbers of migration in three identical experiments by 
Transwell assay. e Effects of MEF2D on A549 proliferation by cell proliferation assay. Data were presented as mean ± S.E.M. of three independent 
experiments. **p < 0.01, as compared with control group
Fig. 6 Effects of signaling pathway inhibitors on LPS‑induced MEF2D expression. a Western blotting analysis of MEF2D protein expression in A549 
cells pretreated with ERK inhibitor PD98059 at doses of 10, 20 and 30 μM for 2 h and then stimulated with LPS (1 μg/ml) for 48 h; b Western blotting 
analysis of MEF2D protein expression in A549 cells pretreated with PI3K inhibitor LY290042 at doses of 10, 20 and 30 μM for 2 h and then stimulated 
with LPS (1 μg/ml) for 48 h. Data were presented as mean ± S.E.M and each group had at least six measurements. *p < 0.05, **p < 0.01, as com‑
pared with control group. +p < 0.05, as compared with LPS group
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lung cancer. MEF2D might be a potential biomarker 
for patients with chronic respiratory diseases, such as 
COPD, who are at risk of developing lung cancer.
However, the present study has some limits. Although we 
adopted an in vitro model based on LPS-stimulated A549 
to mimic inflammatory conditions of airways, there are still 
differences between chronic airway inflammation in  vivo 
and the in vitro model. Much more remains to be learned 
about the regulatory mechanism of MEF2D to communi-
cate between chronic inflammation and lung cancer.
Conclusions
Taken together, the present study demonstrated signifi-
cantly higher MEF2D level in COPD patients with NSCLC 
than that in smokers, patients with COPD and no NSCLC, 
or patients with NSCLC and no COPD. Inflammation 
challenge increased MEF2D expression in A549, associ-
ated with the severity of inflammation, while ERK inhibi-
tion could reverse the up-regulation of MEF2D. MEF2D 
played a critical role in NSCLC cell differentiation, pro-
liferation, or movement. MEF2D might contribute to the 
development of lung cancer through influencing cancer 
microenvironment and cell bio-behaviors during inflam-
matory conditions. MEF2D provides a cross-talk between 
chronic inflammation and lung caner. MEF2D could be a 
potential biomarker predicting risk of lung cancer among 
patient with chronic respiratory diseases. More studies 
are still needed to explore the further mechanism between 
chronic inflammation and lung cancer.
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